Indeed, SGLT2 inhibitors (SGLT2i) reduce plasma glucose levels by inhibiting glucose reabsorption, without targeting the major pathophysiological defects in T2D (insulin resistance and impaired insulin secretion). The gene discussed is INS; the disease is Insulin resistance.